These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35086853)

  • 41. Pefloxacin as a surrogate marker for quinolone susceptibility in
    Sharma P; Dahiya S; Kumari B; Balaji V; Sood S; Das BK; Kapil A
    Indian J Med Res; 2017 May; 145(5):687-692. PubMed ID: 28948961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates.
    Shealy SC; Brigmon MM; Justo JA; Bookstaver PB; Kohn J; Al-Hasan MN
    Antibiotics (Basel); 2020 Apr; 9(4):. PubMed ID: 32316502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
    Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
    Grillon A; Schramm F; Kleinberg M; Jehl F
    PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients.
    Kobayashi K; Yamamoto S; Takahashi S; Ishikawa K; Yasuda M; Wada K; Hamasuna R; Hayami H; Minamitani S; Matsumoto T; Kiyota H; Tateda K; Sato J; Hanaki H; Masumori N; Hiyama Y; Yamada H; Egawa S; Kimura T; Nishiyama H; Miyazaki J; Matsumoto K; Homma Y; Kamei J; Fujimoto K; Torimoto K; Tanaka K; Togo Y; Uehara S; Matsubara A; Shoji K; Goto H; Komeda H; Ito T; Mori K; Mita K; Kato M; Fujimoto Y; Masue T; Inatomi H; Takahashi Y; Ishihara S; Nishimura K; Mitsumori K; Ito N; Kanamaru S; Yamada D; Hiroshi M; Yamashita M; Tsugawa M; Takenaka T; Takahashi K; Oka Y; Yasufuku T; Watanabe S; Chihara Y; Okumura K; Kawanishi H; Matsukawa M; Shigeta M; Koda S
    J Infect Chemother; 2020 May; 26(5):418-428. PubMed ID: 32081647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.
    Bobenchik AM; Deak E; Hindler JA; Charlton CL; Humphries RM
    J Clin Microbiol; 2017 Feb; 55(2):450-456. PubMed ID: 27881616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012-2018.
    Stone GG; Hackel MA
    Ann Clin Microbiol Antimicrob; 2022 Mar; 21(1):13. PubMed ID: 35313912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Anwar S; Nizamuddin S; Malik N; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i76-i87. PubMed ID: 32337594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.
    Pierce VM; Mathers AJ
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):73-80. PubMed ID: 34888640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
    Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surveillance of Wisconsin Antibacterial Susceptibility Patterns.
    Munson E; Block TK; Bowles EJ; Costello M; Dern R; Fritsche TR; Helgesen MA; Kropp JL; Podzorski RP; Siebers K; Simmons B; Smith MA; Spray F; Van TT; Warshauer DM
    WMJ; 2016 Feb; 115(1):29-36. PubMed ID: 27057577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy.
    Qi C; Malczynski M; Schaeffer AJ; Barajas G; Nadler RB; Scheetz MH; Zembower TR
    J Urol; 2013 Dec; 190(6):2026-32. PubMed ID: 23727416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.
    Jean SS; Coombs G; Ling T; Balaji V; Rodrigues C; Mikamo H; Kim MJ; Rajasekaram DG; Mendoza M; Tan TY; Kiratisin P; Ni Y; Weinman B; Xu Y; Hsueh PR
    Int J Antimicrob Agents; 2016 Apr; 47(4):328-34. PubMed ID: 27005459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of Pefloxacin for detection of fluoroquinolone (FQ) resistance among
    Inayath SB; Broor S; Gupta R; Agarwal P; Majumder S; Anveshi AK; Gaind R
    J Med Microbiol; 2021 Aug; 70(8):. PubMed ID: 34356003
    [No Abstract]   [Full Text] [Related]  

  • 59. The impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia.
    Wang KC; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):768-774. PubMed ID: 26493889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
    Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
    Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.